Stockholm - Delayed Quote SEK

Clinical Laserthermia Systems AB (publ) (CLS-B.ST)

Compare
3.8200
+0.0200
+(0.53%)
At close: December 27 at 5:29:49 PM GMT+1
Loading Chart for CLS-B.ST
DELL
  • Previous Close 3.8000
  • Open 3.7000
  • Bid 3.7200 x --
  • Ask 3.7800 x --
  • Day's Range 3.6600 - 3.8800
  • 52 Week Range 3.5200 - 37.6000
  • Volume 74,178
  • Avg. Volume 75,703
  • Market Cap (intraday) 77.048M
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2900
  • Earnings Date Feb 21, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.00

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

www.clinicallaser.se

17

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CLS-B.ST

View More

Performance Overview: CLS-B.ST

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CLS-B.ST
86.16%
OMX Stockholm 30 Index
3.84%

1-Year Return

CLS-B.ST
86.26%
OMX Stockholm 30 Index
4.76%

3-Year Return

CLS-B.ST
98.15%
OMX Stockholm 30 Index
4.38%

5-Year Return

CLS-B.ST
98.82%
OMX Stockholm 30 Index
38.68%

Compare To: CLS-B.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CLS-B.ST

View More

Valuation Measures

As of 7/12/2024
  • Market Cap

    77.05M

  • Enterprise Value

    61.92M

  • Trailing P/E

    1.42

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.86

  • Price/Book (mrq)

    1.26

  • Enterprise Value/Revenue

    3.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -52.36%

  • Return on Equity (ttm)

    -107.80%

  • Revenue (ttm)

    18.63M

  • Net Income Avi to Common (ttm)

    -64.2M

  • Diluted EPS (ttm)

    -2.2900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.58M

  • Total Debt/Equity (mrq)

    2.82%

  • Levered Free Cash Flow (ttm)

    -44.11M

Research Analysis: CLS-B.ST

View More

People Also Watch